Antibody Drug
Conjugates (ADCs)

Antibody Drug Conjugates (ADCs) are now a well established, clinically and commercially proven form of antibody therapeutics allowing the specific tumour delivery of potent cytoxic payloads. After many years, we are seeing many product approvals with the likes of Enhertu and Tivdak driving confidence and momentum. However, despite their success, whole monoclonal antibody (MAb)-based ADCs have intrinsic failings which limit their efficacy in solid tumours, causes unacceptable dose-limiting side-effects and provides for an overall a narrow therapeutic index.

Antikor's unique Antibody Fragment Drug Conjugate (FDC) approach promises to revolutionize solid tumour therapy enabling the next-generation of ADC products in oncology and beyond.

Fragment Drug
Conjugates (FDCs)

With its revolutionary and proprietary OptiLink^TM technology platform, Antikor has adopted a novel approach using much smaller fully-human antibody fragments which can carry high payload loadings leading to a high-DAR (Drug:Antibody Ratio) FDC. This increased potency combined with superior penetration properties and faster valsculature and normal organ elimination makes for potentially best-in-class oncology therapeutics, tailored for difficult-to-treat solid tumours. Antikor's pre-clinical data demonstrate that FDCs have a much wider therapeutic window than conventional ADCs and could revolutionise the way we treat solid tumours. 

Discovery Engine
And Products

Antikor uses proprietary human antibody VH/VL frameworks, optimised for maximal stability and DAR and tailored linker-payloads to generate FDCs which have excellent developability properties. Our Discovery Engine can be used to discover novel FDCs to any given target.

This makes the Antikor FDC-optimized antibody libraries a valuable asset in its own right and the source of future, exciting new products.